A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109

Purpose: Angiogenesis plays an essential role in tumor development, invasion and metastasis. We evaluated the efficacy and safety of dual angiogenesis blockade with bevacizumab and sorafenib in patients with metastatic breast cancer. Patients and Methods: Patients who had received no more than 2 pri...

Descripción completa

Detalles Bibliográficos
Autores principales: Mina, Lida A., Yu, Menggang, Johnson, Cynthia, Burkhardt, Cyndi, Miller, Kathy D., Zon, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771371/
https://www.ncbi.nlm.nih.gov/pubmed/23812905
http://dx.doi.org/10.1007/s10637-013-9976-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771371/
https://www.ncbi.nlm.nih.gov/pubmed/23812905
http://dx.doi.org/10.1007/s10637-013-9976-1

Ejemplares similares